Carbon Dots: A Future Blood–Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier
Wei Zhang,Ganesh Sigdel,Keenan J Mintz,Elif S Seven,Yiqun Zhou,Chunyu Wang,Roger M Leblanc
DOI: https://doi.org/10.2147/IJN.S318732
IF: 7.033
2021-07-23
International Journal of Nanomedicine
Abstract:Wei Zhang, 1, &ast Ganesh Sigdel, 1, &ast Keenan J Mintz, 1 Elif S Seven, 1 Yiqun Zhou, 1 Chunyu Wang, 2, 3 Roger M Leblanc 1 1 Department of Chemistry, University of Miami, Coral Gables, FL, 33146, USA; 2 Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA; 3 Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA &astThese authors contributed equally to this work Correspondence: Roger M Leblanc Email Drug delivery across the blood–brain barrier (BBB) is one of the biggest challenges in modern medicine due to the BBB's highly semipermeable property that limits most therapeutic agents of brain diseases to enter the central nervous system (CNS). In recent years, nanoparticles, especially carbon dots (CDs), exhibit many unprecedented applications for drug delivery. Several types of CDs and CD-ligand conjugates have been reported successfully penetrating the BBB, which shows a promising progress in the application of CD-based drug delivery system (DDS) for the treatment of CNS diseases. In this review, our discussion of CDs includes their classification, preparations, structures, properties, and applications for the treatment of neurodegenerative diseases, especially Alzheimer's disease (AD) and brain tumor. Moreover, abundant functional groups on the surface, especially amine and carboxyl groups, allow CDs to conjugate with diverse drugs as versatile drug nanocarriers. In addition, structure of the BBB is briefly described, and mechanisms for transporting various molecules across the BBB and other biological barriers are elucidated. Most importantly, recent developments in drug delivery with CDs as BBB-penetrating nanodrugs and drug nanocarriers to target CNS diseases especially Alzheimer's disease and brain tumor are summarized. Eventually, future prospects of the CD-based DDS are discussed in combination with the development of artificial intelligence and nanorobots. Keywords: carbon dots, blood–brain barrier, drug delivery, brain tumor, central nervous system diseases Graphical There is a long-lasting question in modern medicine that is how therapeutic agents can penetrate the blood–brain barrier (BBB) to reach and function in the central nervous system (CNS). Due to the BBB's highly semipermeable property, most therapeutic agents of brain diseases are precluded from entering into the CNS. 1 , 2 Alternative strategies such as photodynamic and photothermal therapies have shown possibilities of bypassing the BBB and are used clinically for the treatment of a wide range of brain diseases. However, the side effects of photosensitization and damages to skin tissues raise other concerns. 3 In recent years, the development of nanoparticles (NPs), especially multifunctional smart NPs, has exhibited many unprecedented properties for the application of NP-mediated drug delivery due to their capacities to noninvasively overcome the BBB for the treatment of CNS diseases. 4 The biggest advantage to apply smart NPs is that they can be engineered to react in a predictable and specific way to the external and internal stimuli, which improves the control of the drug delivery process. Moreover, studies have shown that drug delivery efficiency can be greatly enhanced through covalent conjugation of NPs and various ligands. Some ligands such as niosome and glutathione peptide can improve solubility and stability of the NP-based drug delivery systems (DDS). Also, utilization of certain ligands, such as transferrin, can benefit for targeted therapy and the penetration of biological barriers such as the BBB and cell membranes. 5 , 6 Among all the NPs, carbon dots (CDs) are one of the most promising candidates to penetrate the BBB due to their special characteristics, such as high biocompatibility, nontoxicity, abundant surface functional groups, excellent photoluminescence (PL), and nanoscale size. 7–9 Additionally, precursors, synthetic approaches and post-synthesis treatments can also greatly affect their BBB penetration capacity. Multiple studies have reported that CDs can cross the BBB with or without cargo molecules. 10–12 In other words, CDs have exhibited a great potential as versatile drug nanocarriers to cross the BBB and treat the CNS diseases. In this review, the classification and multiple synthetic approaches of CDs are introduced. The special relationships between the precursors and t -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology